This company listing is no longer active
9 Meters Biopharma Crecimiento futuro
Future controles de criterios 2/6
9 Meters Biopharma is forecasted to grow earnings and revenue by 41.4% and 56.6% per annum respectively. EPS is expected to grow by 39.9%. Return on equity is forecast to be -185.6% in 3 years.
Información clave
41.4%
Tasa de crecimiento de los beneficios
39.9%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Pharmaceuticals | 20.3% |
Tasa de crecimiento de los ingresos | 56.6% |
Rentabilidad financiera futura | -185.6% |
Cobertura de analistas | Low |
Última actualización | 30 May 2023 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
9 Meters Biopharma to execute 1-for-20 reverse stock split
Oct 179 Meters Biopharma GAAP EPS of -$0.04 in-line
Aug 159 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome
Jun 149 Meters drug effective in treating rare COVID-19 complication in children
May 269 Meters Bio gains 5% on Adage Capital stake disclosure
Dec 299 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications
Dec 219 Meters Bio launches equity offering
Dec 11Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2025 | N/A | -43 | N/A | N/A | 2 |
12/31/2024 | N/A | -41 | N/A | N/A | 3 |
12/31/2023 | 3 | -43 | N/A | N/A | 4 |
3/31/2023 | N/A | -46 | -37 | -37 | N/A |
12/31/2022 | N/A | -44 | -37 | -37 | N/A |
9/30/2022 | N/A | -41 | -35 | -35 | N/A |
6/30/2022 | N/A | -46 | -36 | -34 | N/A |
3/31/2022 | N/A | -43 | -36 | -33 | N/A |
12/31/2021 | N/A | -37 | -32 | -29 | N/A |
9/30/2021 | N/A | -32 | -30 | -28 | N/A |
6/30/2021 | N/A | -27 | -24 | -24 | N/A |
3/31/2021 | N/A | -63 | -26 | -23 | N/A |
12/31/2020 | N/A | -61 | -23 | -19 | N/A |
9/30/2020 | N/A | -65 | -19 | -16 | N/A |
6/30/2020 | N/A | -66 | -19 | -16 | N/A |
3/31/2020 | N/A | -26 | -16 | -16 | N/A |
12/31/2019 | N/A | -27 | -18 | -18 | N/A |
9/30/2019 | N/A | -22 | -17 | -17 | N/A |
6/30/2019 | N/A | -14 | -17 | -17 | N/A |
3/31/2019 | N/A | -14 | -12 | -12 | N/A |
12/31/2018 | N/A | -24 | -15 | -15 | N/A |
9/30/2018 | N/A | -22 | -15 | -15 | N/A |
6/30/2018 | N/A | -24 | -12 | -12 | N/A |
3/31/2018 | N/A | -23 | -11 | -11 | N/A |
12/31/2017 | N/A | -12 | -5 | -5 | N/A |
9/30/2017 | N/A | -11 | -4 | -4 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: NMTR is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: NMTR is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: NMTR is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: NMTR's revenue (56.6% per year) is forecast to grow faster than the US market (7.5% per year).
Ingresos de alto crecimiento: NMTR's revenue (56.6% per year) is forecast to grow faster than 20% per year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: NMTR is forecast to be unprofitable in 3 years.